Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GMALL Elderly 1/2003 in Acute Lymphoblastic Leukemia
NCT00198978Phase 4Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Jan 2003
- Primary completion
- Jun 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in acute lymphoblastic leukemia (ALL), sponsored by Goethe University Frankfurt. Primary endpoints: Remission rate (cytologic, molecular) at 6 weeks, Toxicity (CTC) and 2 more. Started Jan 2003; status: completed.
02
Drugs
rituximab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00198978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00198978.